Last $28.79 USD
Change Today +0.4901 / 1.73%
Volume 19.5M
PFE On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
Sao Paulo
Bogota
As of 2:50 PM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Business Wire  07/29/2014 8:35 PM ET
INVESTOR ALERT: Investigation of Impax Laboratories, Inc. Announced by Glancy Binkow & Goldberg LLP

LOS ANGELES--(BUSINESS WIRE)--Jul. 29, 2014-- Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Impax Laboratories, Inc. (“Impax” or the “Company”) (NASDAQ:IPXL) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning Impax's business and financial prospects.

Please contact Casey Sadler, Esquire, at (888) 773-9224 or (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

Impax, a specialty pharmaceutical company, develops, manufactures and markets bioequivalent pharmaceutical products, and develops and markets branded products. The investigation relates to the Company's July 29, 2014, disclosure that the Food and Drug Admission (“FDA”) had uncovered potential issues at a facility where the Company would manufacture Rytary, its experimental Parkinson's disease drug. According to the Company, the FDA wants Impax to address a variety of issues at the facility, including problems with equipment, sample testing, rejection of drugs that do not meet the Company's manufacturing standards, and procedures designed to keep microorganisms out of some products. On this news, shares of Impax declined $4.27 per share, 15.23%, to close on July 29, 2014, at $23.76 per share, on unusually heavy volume.

If you purchased shares of Impax, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, by toll-free telephone at (888) 773-9224 or by telephone at (310) 201-9150, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Source: Glancy Binkow & Goldberg LLP

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Casey Sadler
888-773-9224
310-201-9150
shareholders@glancylaw.com
www.glancylaw.com

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:US $28.79 USD +0.494

Industry News

The Planner [Sun Sentinel :: ]

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.